重组人干扰素α-1b治疗小儿轮状病毒感染性肠炎的效果及安全性  

Efficacy and Safety of Recombinant Human Interferonα-1b in the Treatment of Rotavirus Enteritis in Children

作　　者：王春莲[1] 詹玉磊 张景 兰小丰 李苗 杨业勤[1] 时小丽 WANG Chunlian;ZHAN Yulei;ZHANG Jing;LAN Xiaofeng;LI Miao;YANG Yeqin;SHI Xiaoli(Zhijiang People's Hospital,Zhijiang 443200,China;不详)

机构地区：[1]枝江市人民医院,湖北枝江443200

出　　处：《中外医学研究》2024年第23期1-5,共5页CHINESE AND FOREIGN MEDICAL RESEARCH

摘　　要：目的:观察重组人干扰素α-1b治疗小儿轮状病毒感染性肠炎的效果及安全性。方法:选取2022年6月—2023年6月枝江市人民医院收治的186例小儿轮状病毒感染性肠炎,依据随机数表法分为对照组和观察组,各93例。对照组采用临床常规治疗及布拉氏酵母菌散,观察组在对照组基础上采用重组人干扰素α-1b,持续治疗3 d。比较两组治疗3 d后临床疗效,临床症状缓解情况,治疗前、治疗3 d后的肠黏膜损伤指标、肠道菌群、免疫功能,以及研究期间安全性。结果:治疗3 d后,观察组总有效率高于对照组;观察组腹痛消失时间、止泻时间、热退时间早于对照组;治疗3 d后,两组乳杆菌、双歧杆菌和大肠埃希菌菌落数较治疗前均升高,观察组高于对照组,两组粪肠球菌菌落数较治疗前均降低,观察组低于对照组;治疗3 d后,两组血清晚期糖基化终末产物(AGEs)、内毒素(ET)、二胺氧化酶(DAO)水平与治疗前相比均降低,观察组低于对照组;治疗3 d后,两组外周血CD4^(+)、CD4^(+)/CD8^(+)与治疗前相比均升高,观察组高于对照组,外周血CD8^(+)较治疗前均降低,观察组低于对照组;研究期间观察组不良反应发生率低于对照组;上述各指标比较,差异有统计学意义(P<0.05)。结论:在小儿轮状病毒感染性肠炎的临床治疗中,应用重组人干扰素α-1b,能明显改善患儿的临床症状,改善肠道菌群,增强机体免疫力,缓解肠道黏膜损伤,安全性较高,且疗效显著。Objective:To observe the efficacy and safety of Recombinant Human Interferonα-1b in the treatment of rotavirus enteritis in children.Method:A total of 186 children with rotavirus infected enteritis admitted to Zhijiang People's Hospital from June 2022 to June 2023 were selected and divided into control group and observation group according to random number table method,with 93 cases in each group.The control group was treated with clinical routine treatment and Saccharomyces Boulardii Sachets,and the observation group was treated with Recombinant Human Interferonα-1b on the basis of the control group,both group treated for 3 d.The clinical efficacy after 3 d of treatment,the remission of clinical symptoms,the indexes of intestinal mucosal damage,intestinal flora,immune function before and after 3 d of treatment,and the safety during the study were compared between the two groups.Result:After 3 d of treatment,the total effective rate of observation group was higher than that of control group;the time of abdominal pain disappearance,diarrhea prevention and heat regression in the observation group were earlier than those in the control group;after 3 d of treatment,the colony number of Lactobacillus,Bifidobacterium and Escherichia coli in both groups were higher than those before treatment,and the colony number in the observation group were higher than those in the control group,while the Enterococcus faecalis colony number in both groups were lower than those before treatment,and the observation group was lower than the control group;after 3 d of treatment,serum levels of serum advanced glycation end products(AGEs),endotoxin(ET),diamine oxidase(DAO)in both groups were decreased compared with before treatment,and the levels in the observation group were lower than those in the control group.After 3 d of treatment,peripheral blood CD4^(+)and CD4^(+)/CD8^(+)increased in both groups compared with before treatment,the levels in the observation group were higher than those in the control group,peripheral blood CD8^(+)wa

关 键 词：轮状病毒 感染性肠炎 小儿 重组人干扰素 Α-1B 布拉氏酵母菌散 

分 类 号：R725.1[医药卫生—儿科]